Calidi Biotherapeutics Inc (CLDI) poses a Brand-New Opportunity for Investors with beta value of 1.04

Witnessing the stock’s movement on the chart, on Wednesday, Calidi Biotherapeutics Inc (AMEX: CLDI) set off with pace as it heaved 3.03% to $1.36, before settling in for the price of $1.32 at the close. Taking a more long-term approach, CLDI posted a 52-week range of $0.58-$16.80.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that the giant of the Healthcare sector posted annual sales growth of -50.00% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is 78.64%. This publicly-traded company’s shares outstanding now amounts to $93.11 million, simultaneously with a float of $16.88 million. The organization now has a market capitalization sitting at $35.25 million. At the time of writing, stock’s 50-day Moving Average stood at $1.4030, while the 200-day Moving Average is $1.5907.

Calidi Biotherapeutics Inc (CLDI) Ownership Facts and Figures

Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Calidi Biotherapeutics Inc’s current insider ownership accounts for 10.45%, in contrast to 2.67% institutional ownership. According to the most recent insider trade that took place on Dec 17 ’24, this organization’s CEO and Chairman of the Board sold 10,000 shares at the rate of 1.62, making the entire transaction reach 16,200 in total value, affecting insider ownership by 66,712.

Calidi Biotherapeutics Inc (CLDI) Earnings and Revenue Records

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.

Calidi Biotherapeutics Inc’s EPS increase for this current 12-month fiscal period is 78.64% and is forecasted to reach -0.78 in the upcoming year.

Calidi Biotherapeutics Inc (AMEX: CLDI) Trading Performance Indicators

Let’s observe the current performance indicators for Calidi Biotherapeutics Inc (CLDI). It’s Quick Ratio in the last reported quarter now stands at 0.19. The Stock has managed to achieve an average true range (ATR) of 0.19.

In the same vein, CLDI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.81, a figure that is expected to reach -0.37 in the next quarter, and analysts are predicting that it will be -0.78 at the market close of one year from today.

Technical Analysis of Calidi Biotherapeutics Inc (CLDI)

Going through the that latest performance of [Calidi Biotherapeutics Inc, CLDI]. Its last 5-days volume of 6.55 million indicated improvement to the volume of 2.29 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 85.61% While, its Average True Range was 0.2035.

Raw Stochastic average of Calidi Biotherapeutics Inc (CLDI) in the period of the previous 100 days is set at 23.56%, which indicates a major fall in contrast to 84.78% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 195.29% that was higher than 184.27% volatility it exhibited in the past 100-days period.